These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 31846941)
1. Enhanced in vitro antitumor efficacy of a polyunsaturated fatty acid-conjugated pH-responsive self-assembled ion-pairing liposome-encapsulated prodrug. Wang Y; Fan P; Zhu L; Zhuang W; Jiang L; Zhang H; Huang H Nanotechnology; 2020 Apr; 31(15):155101. PubMed ID: 31846941 [TBL] [Abstract][Full Text] [Related]
2. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy. Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081 [TBL] [Abstract][Full Text] [Related]
3. Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy. Lei J; Cong S; Song M; Zhang W; Peng G; Li X; Liu Y Drug Dev Ind Pharm; 2018 Apr; 44(4):570-581. PubMed ID: 29260918 [TBL] [Abstract][Full Text] [Related]
5. Dong Y; Du P; Liu P Int J Pharm; 2020 Oct; 588():119723. PubMed ID: 32755688 [TBL] [Abstract][Full Text] [Related]
6. Lipoic acid-derived cross-linked liposomes for reduction-responsive delivery of anticancer drug. Ling L; Ismail M; Du Y; Yao C; Li X Int J Pharm; 2019 Apr; 560():246-260. PubMed ID: 30769133 [TBL] [Abstract][Full Text] [Related]
7. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release. Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663 [TBL] [Abstract][Full Text] [Related]
8. Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity. Zhang B; Wan S; Peng X; Zhao M; Li S; Pu Y; He B J Mater Chem B; 2020 May; 8(17):3939-3948. PubMed ID: 32236239 [TBL] [Abstract][Full Text] [Related]
9. Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers. Jin Y; Wang Y; Liu X; Zhou J; Wang X; Feng H; Liu H Drug Des Devel Ther; 2020; 14():5205-5215. PubMed ID: 33268983 [TBL] [Abstract][Full Text] [Related]
10. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery. Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909 [TBL] [Abstract][Full Text] [Related]
11. Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer. Abazari R; Mahjoub AR; Ataei F; Morsali A; Carpenter-Warren CL; Mehdizadeh K; Slawin AMZ Inorg Chem; 2018 Nov; 57(21):13364-13379. PubMed ID: 30351060 [TBL] [Abstract][Full Text] [Related]
12. Photo- and pH- Dual-Responsive β-Cyclodextrin-Based Supramolecular Prodrug Complex Self-Assemblies for Programmed Drug Delivery. Bai Y; Liu CP; Song X; Zhuo L; Bu H; Tian W Chem Asian J; 2018 Dec; 13(24):3903-3911. PubMed ID: 30311448 [TBL] [Abstract][Full Text] [Related]
13. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502 [TBL] [Abstract][Full Text] [Related]
15. Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property. Xu H; Zhang L; Li L; Liu Y; Chao Y; Liu X; Jin Z; Chen Y; Tang X; He H; Kan Q; Cai C AAPS PharmSciTech; 2017 Aug; 18(6):2120-2130. PubMed ID: 28028795 [TBL] [Abstract][Full Text] [Related]
16. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier. Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251 [TBL] [Abstract][Full Text] [Related]
17. GSH/pH dual-responsive biodegradable camptothecin polymeric prodrugs combined with doxorubicin for synergistic anticancer efficiency. Li J; Hu ZE; Yang XL; Wu WX; Xing X; Gu B; Liu YH; Wang N; Yu XQ Biomater Sci; 2019 Aug; 7(8):3277-3286. PubMed ID: 31180396 [TBL] [Abstract][Full Text] [Related]
18. A pH-responsive prodrug delivery system self-assembled from acid-labile doxorubicin-conjugated amphiphilic pH-sensitive block copolymers. Huang X; Liao W; Xie Z; Chen D; Zhang CY Mater Sci Eng C Mater Biol Appl; 2018 Sep; 90():27-37. PubMed ID: 29853091 [TBL] [Abstract][Full Text] [Related]
19. Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity. Zhang A; Yao L; An M Chem Commun (Camb); 2017 Nov; 53(95):12826-12829. PubMed ID: 29143021 [TBL] [Abstract][Full Text] [Related]
20. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design. Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]